The reaffirmed Buy rating and maintained $8 price target by HC Wainwright & Co. analyst Edward White indicates a positive outlook for Puma Biotechnology's stock. This news is directly related to PBYI and is important for investors as it reflects the analyst's confidence in the company's potential growth. The score of 1 suggests a likely increase in stock price in the short term.